source
- STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting downRecent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.STAT · 13d ago↗ source
- Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMORoche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting. The study evaluated divarasib in patients with advanced non-small cell…